Goldman Ends Endo Coverage Following Q2 EBITDA Guide

NY-Based Investment Bank Halves Its 2023 Vasostrict Sales Guide

One of the largest investment banks in the US has cancelled its coverage of Endo after the US-based firm revealed the extent of generic competition to its lucrative Vasostrict brand.

Endo shares had been 'sent reeling' • Source: 360b/Shutterstock

Goldman Sachs is to cease coverage of struggling Endo International plc. The move follows the US-based firm guiding for its adjusted EBITDA to fall by as much as 65% quarter-over-quarter in the wake of generic competition to its $900m Vasostrict (vasopressin) injectable.

The New York-based investment bank typically publishes a report of Endo’s quarterly financial results and other material events. But it...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business

Neuraxpharm Targets Asia-Pacific In Latest Phase Of Expansion Beyond Europe

 
• By 

Neuraxpharm has launched its Australian affiliate as part of its continued international expansion beyond Europe. The company will introduce CNS treatments including its acquired Nuvigil, Provigil, and the recently TGA-approved Briumvi for multiple sclerosis.

The Generics Bulletin Top 50, Part Two: Leading Players Leapfrog The Competition

 
• By 

In the second instalment of Generics Bulletin’s Top 50 ranking for 2025, we see plenty of movement among our mid-table collection of companies.

Gateway To Africa: Natco Bids For 35.75% Of Adcock Ingram

 

Natco to buy out Adcock Ingram’s minority shareholders in what’s possibly its biggest M&A investment, opening up substantial opportunities in South Africa and the region. If the offer goes through, it will result in the delisting of Adcock, with Bidvest and Natco co-owning the firm.

The Generics Bulletin Top 50, Part One: German Giants Rise Up The Ranks

 
• By 

Two leading German generics and biosimilars giants were the big movers in our top ten ranking of off-patent industry leaders for 2025. We reveal the latest developments among the top players in the first instalment of this year’s Generics Bulletin Top 50.

More from Generics Bulletin